Page 357 - Binder2

But today, most large pharmaceutical companies don’t
disrupt anymore—they acquire.

Over the last two decades, the prevailing strategy has
shifted from internal invention to external acquisition.
Companies now function less like laboratories of
innovation and more like consolidation platforms. They
monitor the biotech ecosystem for validated programs, wait
for early clinical success, and then swoop in to license or
acquire—once the science is de-risked and the revenue
model is clear.

It’s not a failure of imagination.
It’s a strategy of optimization—designed to minimize risk
and maximize shareholder returns.

And in most cases, it works.
But not for edible biologics.

Edible Biologics Don’t Fit the Script

Edible biologics don’t play by the same rules. They are not
simply new molecules waiting to slot into existing delivery
systems. They are not plug-and-play assets that fit inside an
injectable franchise or an oncology division.

They are a new philosophy:

● A shift from centralized to distributed
manufacturing.
● A shift from high-margin pricing to mass
accessibility.
● A shift from biologics as sterile, purified injectables
to edible, shelf-stable capsules.

355